<DOC>
	<DOCNO>NCT00157703</DOCNO>
	<brief_summary>This open-label , single site study evaluate safety tolerability intratumoral administration G207 follow treatment radiation therapy patient recurrent/progressive malignant glioma . This study two stage phase 1 study , de-escalating dosing scheme use , i.e . first patient receive high dose excessive toxicity occur , dose reduce following patient . The purpose dose de-escalation phase find best safe dose G207 . In first stage study , treatment G207 follow focal radiation therapy follow day , second stage treatment G207 follow gamma knife surgery also follow day . All patient return clinic 28 day 3 , 6 , 9 12 month G207 administration time clinical assessment perform , follow safety survival clinic visit telephone every 3 month 2 additional year annually thereafter .</brief_summary>
	<brief_title>G207 Followed Radiation Therapy Malignant Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>1 . Pathologically proven residual/recurrent glioblastoma multiforme , gliosarcoma anaplastic astrocytoma progressive despite radiotherapy chemotherapy 2 . Failed external beam radiotherapy &gt; 5,000 CGy least 4 week prior enrollment 3 . Residual/recurrent lesion must ≥ 1.0 cm ( Stage 2 ) ≤ 4 cm diameter determine magnetic resonance imaging ( MRI ) 4 . Normal hematological , renal liver function Absolute neutrophil count &gt; 1500/mm3 Platelets &gt; 100,000/mm3 Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &lt; 1.3 x control Creatinine &lt; 1.7 mg/dl Total bilirubin &lt; 1.5 mg/dl Transaminases &lt; 4 time upper limit institutional norm 5 . Karnofsky Performance Status score ≥ 70 6 . Age &gt; 19 yearsold 7 . Capable give informed consent 8 . Must willing practice effective barrier method birth control 2 month post G207 inoculation , whether male female 9 . Females childbearing potential : negative pregnancy test within 24 hour prior G207 administration 1 . Surgical resection within 4 week enrolment 2 . Acute infection , granulocytopenia medical condition preclude surgery 3 . Pregnant lactating female 4 . History encephalitis , multiple sclerosis , central nervous system ( CNS ) infection 5 . Tumor involvement would require ventricular , brainstem , basal ganglion , posterior fossa inoculation would require access ventricle order deliver treatment tumor involve hemisphere subependymal/cerebral spinal fluid ( CSF ) dissemination 6 . Tumor position could , Investigator 's opinion , pose risk penetration cerebral ventricular system inoculation study drug ( Note : If penetration ventricular system suspect confirm , G207 administration must abort . ) 7 . Tumor location would expose patient unacceptable risk radiation therapy 8 . Prior participant experimental viral therapy ( e.g. , adenovirus , retrovirus herpesvirus protocol ) 9 . Prior participant chemotherapy , cytotoxic therapy , immunotherapy gene therapy protocol within 6 week enrolment 10 . Required steroid increase within 2 week prior injection 11 . HIV seropositive 12 . Concurrent therapy drug active herpes simplex virus ( HSV ) ( acyclovir , valaciclovir , penciclovir , famciclovir , ganciclovir , foscavir , cidofovir ) 13 . Active oral genital herpes lesion 14 . Any contraindication undergo MRI pacemaker , infusion pump , ferromagnetic aneurysm clip , metal prosthesis , etc . 15 . Radiation treatment volume great 4 cm maximum diameter ( Stage 2 )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Malignant glioma</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>GBM</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Anaplastic astrocytoma</keyword>
	<keyword>Brain cancer</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Glioma</keyword>
	<keyword>recurrent/progressive malignant glioma</keyword>
</DOC>